YOUTUBE (CNN) - Gov. Pritzker says a GLP-1 helped him lose 80 pounds
Illinois Gov. JB Pritzker (D) revealed Monday on “CBS Mornings” that he has been taking a GLP-1 medication since he was diagnosed with diabetes two years ago.
WASHINGTONPOST (Julie Z. Weil) - Why it may become harder to get coverage for GLP-1 weight-loss drugs
For those who rely on the medications, the difference between health plans that cover them and those that don't can mean hundreds of dollars a month.
NYTIMES (Dani Blum) - What Older Adults Should Know About GLP-1 Drugs as Medicare Coverage Expands
A Medicare pilot beginning Wednesday will broaden access to medications like Wegovy and Zepbound. There are unique risks for those over 65.
AXIOS (Tina Reed) - Medicare weight-loss drug coverage could overwhelm doctors
Next month's launch of a Medicare program providing weight-loss drugs for $50 a month is expected to unleash pent-up demand for Wegovy, Zepbound and other blockbuster treatments — and create new bottlenecks at doctors' offices. The big picture: It could become one of the biggest drug rollouts ever — and it could test an already burdened system as seniors seek new GLP-1 prescriptions. - Clinicians worry that could also give short shrift to patient counseling on how to take the injectables and pills, adjust dosages and deal with side effects. - Medicare has been prohibited by law from covering weight-loss drugs. Where it stands: The new program is part of a deal President Trump struck with Eli Lilly and Novo Nordisk to cut prices for…
Next month's launch of a Medicare program providing weight-loss drugs for $50 a month is expected to unleash pent-up demand for Wegovy, Zepbound and other blockbuster treatments — and create new bottlenecks at doctors' offices. The big picture: It could become one of the biggest drug rollouts ever — and it could test an already burdened system as seniors seek new GLP-1 prescriptions. - Clinicians worry that could also give short shrift to patient counseling on how to take the injectables and pills, adjust dosages and deal with side effects. - Medicare has been prohibited by law from covering weight-loss drugs. Where it stands: The new program is part of a deal President Trump struck with Eli Lilly and Novo Nordisk to cut prices for…Open
NPR (Yuki Noguchi) - Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it
A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs.
A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs.Open
NPR (Yuki Noguchi) - What does a 'GLP-1 Friendly' diet look like? We asked nutritionists
Big food companies are starting to market to people on the powerful new obesity meds with labels that say "GLP-1 Friendly." Nutritionists help us decode that message.
Big food companies are starting to market to people on the powerful new obesity meds with labels that say "GLP-1 Friendly." Nutritionists help us decode that message.Open
NYTIMES (Simar Bajaj and Dani Blum) - When Weight-Loss Drugs Don’t Work
Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call “non-responders.”
WASHINGTONPOST (Christopher Rowland) - How GLP1s are changing the ways Americans buy medicine
Consumers are paying in cash in a hotly competitive marketplace, creating a rare phenomenon for a relatively new class of prescription drugs: falling prices.
NPR (Yuki Noguchi) - Using GLP-1s to maintain a normal weight? There are benefits and risks
Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric surgery to keep pounds from creeping back. Others may just want to lose a few pounds.
NPR (Yuki Noguchi) - GLP-1 drugs don't work for everyone. But personalized obesity care in the future might
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now.
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now.Open